Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Out-RANKing BRCA1 in Mutation Carriers.

Cancer research - 1 Feb 2017

Nolan Emma, Lindeman Geoffrey J, Visvader Jane E

Abstract excerpt

Beyond prophylactic mastectomy, there are currently very few options available to BRCA1 mutation carriers to help reduce their risk of developing breast cancer. An effective prevention therapy therefore remains a pressing area of need. Accumulating evidence points to amplification of the progesterone signaling axis in precancerous tissue from BRCA1 mutation carriers. Given that RANKL is an important paracrine...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA1 Protein
Share to Breast Neoplasms
Share to Cell Transformation, Neoplastic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to BRCA1 gene

Share to Genetic Predisposition to Disease

Share to Heterozygote

Share to Receptor Activator of Nuclear Factor-kappa B

Source

Identifiers

PMID: 28104682
DOI: 10.1158/0008-5472.CAN-16-2025

Genes

BRCA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Out-RANKing BRCA1 in Mutation Carriers.PMID 28104682Read ↗

RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers.Semantic proximity Read ↗

NF-κB at the Crossroads of Normal Mammary Gland Biology and the Pathogenesis and Prevention of BRCA1-Mutated Breast Cancer.Semantic proximity Read ↗

Can we prevent BRCA1-associated breast cancer by RANKL inhibition?Semantic proximity Read ↗

RANKL/RANK control Brca1 mutation- .Semantic proximity Read ↗

RANKL/OPG in Breast Cancer - Extending Its Territory to BRCA Mutation Carriers.Semantic proximity Read ↗

Loss of glucocorticoid receptor activation is a hallmark of BRCA1-mutated breast tissue.Semantic proximity Read ↗

Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers.Semantic proximity Read ↗

Plasma osteoprotegerin and breast cancer risk in BRCA1 and BRCA2 mutation carriers.Semantic proximity Read ↗

Increased Progesterone Receptor Expression in Benign Epithelium of BRCA1 -Related Breast CancersSemantic proximity Read ↗

RANKL/RANK: from bone loss to the prevention of breast cancer.Semantic proximity Read ↗

Genetic predisposition directs breast cancer phenotype by dictating progenitor cell fate.Semantic proximity Read ↗

Prevention of breast cancer by RANKL/RANK blockade.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.